Paul Chaplin, Bavarian Nordic CEO

US con­sid­ers use of ex­pired mon­key­pox vac­cines amid ris­ing de­mand for dos­es

As the US looks to stretch its stock­pile of Bavar­i­an Nordic’s mon­key­pox vac­cine, reg­u­la­tors are work­ing with the com­pa­ny to as­sess whether some ex­pired dos­es …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.